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ABSTRACT 
 
Rachel Elaine Vaughan:  Biomarkers of Lung Epithelial Damage After Inhalation Injury 
(Under the direction of Bruce Cairns and Robert Maile) 
 
 Burn and inhalation injury affects almost half a million people in the United States each 
year and it is one of the most complicated forms of trauma to treat.  Further research is needed 
in order to better understand the precise mechanisms behind both burn and inhalational injury, 
as well as means by which to more accurately stratify patients by injury severity in order to care 
for them more effectively.  In this study, I examine two potential biomarkers in mice with 
possible translational relevance that could be of use in quantifying injury severity in 
hospitalized patients.  IL-33 and 8-isoprostane may be indicators of acute and long-term 
damage, respectively.  IL-33 is elevated at twenty-four hours post-injury in mice with inhalation 
injury, while 8-isoprostane is elevated in mice with combined burn + inhalation injury at two 
weeks post-injury.  These data may begin to provide a method for better patient evaluation and 
improved outcome. 
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CHAPTER 1:  INTRODUCTION 
 Burn injury affects approximately 450,000 individuals in the United States per year, of 
which around 50,000 are hospitalized1.  This comes at a cost of roughly $7.5 billion dollars and 
presents with a complex pathology affecting multiple organs and systems1,2.  Burn injury, 
however, frequently presents with other comorbidities, most commonly inhalational injury 
from smoke2.  Therefore, it is necessary to understand the pathophysiology underlying 
inhalational injury alone, as well as in conjunction with burn in order to better understand how 
best to treat hospitalized patients.  I hypothesize that smoke inhalation causes increased 
damage to the lung epithelial cells, resulting in the release of cytokines.  These biomarkers can 
then be used to assist in stratifying hospitalized patients by injury severity, thereby allowing for 
improved treatment efficacy. 
 Inhalational injury has changed along with the smoke toxicity over the past few decades 
as increasing numbers of products are manufactured with synthetic materials, causing them to 
burn hotter, faster, and to release more chemicals into the air that can potentially be inhaled 
and cause further damage2.  This heterogeneity of combustion products complicates both 
research into and treatment of inhalation injury.  Previously, animal models have included 
mice, rats, sheep, and pigs, however the most commonly used source of smoke in these studies 
is cotton, which does not adequately recapitulate the conditions of a human exposed to a 
housefire or similar environment2–4.   
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 Inhalation injury in humans is characterized by possible thermal injury to and/or 
chemical irritation limited to the upper airway5.  Toxic compounds present in the combustion 
products (e.g. aldehydes, carbon monoxide, hydrochloric acid, oxides, etc.) may cause damage 
to the lung parenchyma and interfere with gas exchange in the lung, further complicating 
treatment5.  In the lower airways, thick mucous collects and lung epithelial cells slough off of 
the basement membrane (Figure 1)5.  Neutrophils infiltrate into the alveolar spaces and release 
reactive oxygen species (ROS), which may cause further damage to the lung tissue3,5.  Severe 
inhalation injury or burn may also lead to acute lung injury (ALI), in which a patient suffers from 
impaired gas exchange, reduced airway compliance, increased pulmonary vascular resistance, 
edema, and neutrophil sequestration in the lung tissue6. 
 
 There is currently no standardization for severity of lung injury or biomarkers to identify 
patients with a greater degree of lung tissue damage.  Most treatment centers rely heavily on 
the use of a bronchoscope to visually evaluate the large airways, looking for debris 
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accumulation, mucous buildup, and epithelial damage, such as can be seen in Figure 1.  
Additionally, the Baux score—a system used to predict mortality from burn injury based on the 
percent of total body surface area (TBSA) burned and the patient’s age—immediately adds 17 
for inhalation injury.  A score of 140 is considered to be unsurvivable.  While these measures 
are of some benefit, a more precise method for determining injury severity and patient 
outcomes would be of enormous use in targeting treatment for individual patients. 
 Thus far, animal models have been unable to completely mimic the human 
pathophysiology and so we developed a mouse model of inhalation injury that more closely 
approximates the human inhalation injury in order to better understand the underlying 
mechanisms of injury.  This allows for a more focused effort at identifying potential biomarkers 
of lung injury as well as evaluating possible interventions to improve patient outcome.   
 Despite the obvious differences in scale and differences in the nasal passages between 
mice and humans, they share key similarities that make mouse models a viable option for burn 
and inhalation injury.  These include similarities in cytokine and chemokine production, and 
leukocyte activation7.  From histological images of the alveolar space and large airways, we 
know that inhalation injury in mice causes the same type of damage as that seen in humans—a 
disrupted epithelial layer, detached basement membrane, vacuolization, cell death, and the 
presence of debris and inflammatory infiltrate (Figure 2). 
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 One possible biomarker that could be of use in indicating injury severity is IL-33, a 
nuclear cytokine in the IL-1 family that is expressed in epithelial barrier tissues and lymphoid 
organs8.  It has been observed in humans and mouse models of asthma and activates Myd88-
dependent signaling pathways in target cells expressing ST2/IL-1RAcP receptor complex8,9.  
Such target cells include natural helper cells, innate helper 2 cells, mast cells, basophils, 
eosinophils, TH2 cells, NKT and NK cells8.  In a mouse model of ALI, IL-33 pretreatment 
decreases the survival rate of the mice, increases proinflammatory cytokines TNF-α and IL-6, 
and increases myeloperoxidase (MPO) levels in lung tissue9.  Furthermore, IL-33 pretreatment 
destroys adherens junctions, thereby causing increased pulmonary capillary barrier damage and 
pulmonary edema9.   
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 8-isoprostane may also be a good indicator of oxidative stress in lung tissues and 
elevated levels have  been observed in breath condensate, plasma, sputum, and urine in cystic 
fibrosis, inflammatory airway diseases, and other cases of lung injury10–12.  Oxidative damage to 
lipids leads to the production of isoprostanes, including 8-isoprostane11.  These isoprostanes 
have frequently been used in other models as a reliable indicator of oxidative stress, as they are 
structurally stable, produced in vivo, and are a common feature of respiratory disease11. 
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CHAPTER 2:  METHODS 
 Female C57BL/6 mice from 8-10 weeks old and weighing 18-21 g were obtained from 
Taconic Farms and housed in pathogen-free facilities.  All protocols were approved by the 
University of North Carolina at Chapel Hill’s Institutional Animal Care and Use Committee and 
were verified to follow guidelines from the National Institute of Health concerning use of 
vertebrate animals in research.   
Inhalation protocol 
 Mice were anesthetized with tribromoethanol (avertin) (475 mg/kg body weight; Sigma-
Aldrich).  Their backs were then closely shaved to expose the skin and they were given a 
subcutaneous injection of morphine sulfate (3 mg/kg body weight; Westward).  They were each 
given an unique ear tag identifier and ophthalmic ointment was applied to their eyes.  Mice 
were then placed on an intubation platform and intubated with a catheter (22G x 1”, Exel) into 
the trachea following visualization with a laryngoscope.  Mice were secured to a platform in a 
supine position with Velcro straps placed loosely across the chest and placed into an animal 
induction chamber (Stoelting NC9296517).  Approximately 50g of 2.5 cm x 8 cm sections of 
particle board were placed into a side-arm flask on a heat block set to 500C, causing the wood 
to smolder and emit smoke.  Additional wood was added as necessary to maintain visual smoke 
density.  Air was pumped through the flask and into the induction chamber for three exposures 
of two minutes each with a one minute break between exposures.  The entire inhalation 
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apparatus was set up and maintained in a dedicated fume hood.  Mice were resuscitated with 
an intraperitoneal injection of lactated Ringer’s solution (1 mL/kg body weight; Baxter 
Healthcare Incorporated) and allowed to recover on a heating pad.  Mice were maintained for 
the duration of the experiment on morphinated water available at all times in their cages.  
Sham mice were treated identically, except for the lack of smoldering wood in the flask; instead 
pure air was pumped through the system.  At time of tissue harvest, mice were euthanized with 
gaseous isofluorane. 
Burn protocol 
 Burned mice were prepared in exactly the same manner as the inhalation mice (above), 
except that instead of being intubated, they were given a 20% TBSA burn with four applications 
of a copper rod heated in a 100C water bath and dried immediately prior to application to avoid 
scald injury.  They were resuscitated and maintained on morphinated water identically to the 
inhalation injury mice. 
Broncho-alveolar lavage sample acquisition and processing 
 Broncho-alveolar lavage fluid (BALF) was collected by inserting a 22G x 1” catheter into 
the trachea connected to a syringe containing 1 mL 0.6 mM EDTA in PBS.  .7 mL was flushed 
into the lungs, massaged through the lungs by chest palpitations, and then withdrawn.  This 
same 1 mL fluid was flushed a total of three times through the lungs to obtain a primary wash.  
Typical recovery was 0.75 mL.  This procedure was repeated with two more syringes of fluid 
and combined to form a secondary wash with a recovery of around 1.8 mL.  Cells were pelleted 
out and stored at -80C and the cell-free supernatant from the primary wash was stored at -20C 
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for later analysis via enzyme-linked immune-sorbent assay (ELISA) for IL-33 (R&D) and 8-
isoprostane (Cayman Chemical) according to the manufacturer’s instructions. 
Whole lung acquisition and processing 
 Lungs were removed from mice after the BALF was extracted.  Lungs were suspended in 
0.5 mL PBS, 0.005% BHT, and bullet blender beads (Next Advance).  Lungs were then placed in 
the Bullet Blender (Next Advance) for 5 minutes.  Homogenized tissue was then centrifuged to 
pellet out solid material and the supernatant was extracted and stored at -20C for later analysis 
via ELISA for IL-33 (R&D) and 8-isoprostane (Cayman Chemical). 
Statistical analysis 
 GraphPad Prism was used to analyze data via Student’s t-test, one-way analysis of 
variance (ANOVA) with Tukey post-test, as appropriate.  Data are represented as mean +/- 
standard error of the mean (SEM).  Statistical significance is indicated as * p<0.05 and ** 
p<0.005. 
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CHAPTER 3:  RESULTS 
8-isoprostane in BALF is increased after burn + inhalation injury at two weeks post-injury 
 Following burn, inhalation injury, and combined burn + inhalation injury, total 8-
isoprostane levels in whole lung (WL) homogenate supernatant remains unchanged at 500 
pg/mL to 600 pg/mL from twenty-four hours through two weeks post-injury (Figure 3).  
However, levels of 8-isoprostane in the BALF were significantly increased (p<0.05) in the 
combined burn + inhalation treated mice (Figure 4).  No differences were observed at twenty-
four or ninety-six hours post-injury. 
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IL-33 in BALF is increased in inhalation injury at 24 hours post-injury 
 Total IL-33 in WL homogenate supernatant also remains unchanged throughout the 
duration of the experiment (Figure 5).  Levels of IL-33 remain fairly consistent between 500 
pg/mL to 600 pg/mL.  BALF levels of IL-33 indicated a greater sensitivity to injury than the WL 
homogenate supernatant and there is a significant increase in BALF IL-33 at twenty-four hours 
post-injury (p<0.005) in the inhalation treated mice and an increase (p<0.08) at two weeks 
post-injury in the burned mice (Figure 6).  Time points at less than twenty-four hours indicated 
no significant differences between groups. 
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CHAPTER 4:  DISCUSSION, LIMITATIONS, AND FUTURE DIRECTIONS 
 From these data, 8-isoprostane appears to be a possible indicator of late damage 
following burn + inhalation injury.  This may be due to oxidative damage from neutrophil 
infiltration and subsequent release of ROS into the lung tissues.  The released ROS may be 
causing further damage to compromised lung tissue, thereby triggering the release of 8-
isoprostane into the BALF. 
We further conclude that IL-33 may be an indicator of acute damage to the lung 
epithelium following the inhalation injury.  This may be due to direct injury from particulate 
matter in the smoke and/or damage from toxic chemicals released from the particle board 
during combustion.  The rise in IL-33 in burn at two weeks post-injury may be an indicator of 
secondary systemic effects of the burn as the body becomes immune-compromised and cannot 
continue to adequately support normal lung tissue maintenance. 
In addition to its well-documented role as a pro-inflammatory cytokine and alarmin, IL-
33 may also play a role in driving an early anti-inflammatory response that promotes healing, 
similar to that seen in IL-10 in human studies of burn trauma13.  This mechanism may involve 
sequestration of NF-κB, thereby reducing NF-κB-triggered gene expression and dampening 
proinflammatory signaling14.  Such dampening of the protective pro-inflammatory responses 
shortly after injury may result in an increased susceptibility to later infection, a common serious 
complication of burn injury13.   
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This study is limited by the inability to provide major supportive care following injury to 
the mice and the ethical limitations on the severity of injury that can be studied.  Mice could 
not be mechanically ventilated or have blood gases monitored and those with the most severe 
injuries were euthanized prior to the completion of the study.  This limits the relationship to 
human burn patients who have access to such advanced supportive care following injury.  A 
larger sample size at an increased number of timepoints may also improve the precision of the 
results and provide greater insights into the mechanism of the injury. 
 Future studies will include the assessment of serum as another easily available means by 
which to look for possible biomarkers to evaluate patient injury severity, as well as expanding 
the screen for other potential candidates.  We also plan to evaluate human samples and 
compare them directly with the results seen in mice in order to ensure that any good biomarker 
candidates are translationally relevant.  Additional studies to determine the level of ROS in the 
lung following injury and then blocking neutrophil infiltration and re-testing the level of ROS 
may be useful in determining the cause of damage, particularly at later time points.  Finally, a 
precise chemical analysis of the smoke produced from combustion of the particle board could 
provide insights into the most relevant toxins that may be inhaled and allow for better patient 
stratification based on the source of combustion materials in inhalation and combined injury.  
We hypothesize that the combustion of synthetic products and chemicals will result in an 
increase in mortality and hospital stay. 
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